Lonneke van de Poll

Today, 10 million people in Europe survive cancer for 5 years or longer, being at risk for a range of adverse effects. However, our understanding of health decline (symptom development, deteriorated quality of life, functional decline, disease progression and onset of comorbidity) after cancer is still in its infancy.

The overarching goal of our research is to understand which patients are vulnerable to develop long-term and late effects of cancer treatment, and to investigate interventions that can prevent or alleviate these negative health outcomes.